Global Drug Delivery Market - Trends and Forecast to 2022
Synopsis:
Global Drug Delivery Devices Market is expected to reach USD 1625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 728 pages of exclusive premium insights with 960 tables and 54 figures.
Global Drug Delivery Devices Market is segmented based on product type, end-user, distribution channel, and geography.
On the basis of product type, the drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal.
Based on end-users the market is segmented into hospitals, clinics, home healthcare, community healthcare, and others.
On the basis of distribution channel the market is segmented into hospital pharmacy, pharmacy stores, direct tenders, and online pharmacy.
The global drug delivery devices market is segmented into 5 regions such as North America, Europe, Asia-Pacific, South America and Middle East and Africa. These regions are further classified on the basis of country, into major countries such as U.S., Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Major Players Operating in this market:
Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others .
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa( South Africa, Rest of MEA)).
Global Drug Delivery Devices Market is expected to reach USD 1625.1 billion by 2022, at a CAGR of 8.0% during the forecast period of 2016 to 2022. The report contains 728 pages of exclusive premium insights with 960 tables and 54 figures.
Global Drug Delivery Devices Market is segmented based on product type, end-user, distribution channel, and geography.
On the basis of product type, the drug delivery devices market is segmented into oral, injectable, topical, pulmonary, nasal, ocular, implantable and transmucosal.
Based on end-users the market is segmented into hospitals, clinics, home healthcare, community healthcare, and others.
On the basis of distribution channel the market is segmented into hospital pharmacy, pharmacy stores, direct tenders, and online pharmacy.
The global drug delivery devices market is segmented into 5 regions such as North America, Europe, Asia-Pacific, South America and Middle East and Africa. These regions are further classified on the basis of country, into major countries such as U.S., Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Major Players Operating in this market:
Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc. , Merck & Co., Sanofi, Antares Pharma, 3M, Becton Dickinson and Company, Nemera, Cima Labs, Inc., Dali Medical Devices, Alkermes, Foamis, Ypsomed, Skyepharma AG, Valeant Pharmaceuticals DSM Biomedical and Catalent, Inc. among others .
Regions Covered In The Scope Of The Report:
Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa( South Africa, Rest of MEA)).
1 INTRODUCTION
1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL DRUG DELIVERY DEVICES MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL DRUG DELIVERY DEVICES MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
4.3.1.2. TECHNOLOGICAL DEVELOPMENT AND GROWTH IN BIOLOGICS
4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
4.3.2. RESTRAINTS
4.3.2.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
4.3.2.2. HIGH PRICING OF PATENTED DRUGS AND LIMITED AVAILABILITY
4.3.3. OPPURTUNITIES
4.3.3.1. RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
4.3.3.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
4.3.3.3. RISING TREND OF ACQUISITION
4.3.3.4. FOCUS ON PATEINT NEEDS
4.3.3.5. DEVELOPING AND NEW EMERGING REVENUE POCKETS
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. EXPENSIVE AND STRINGENT REGULATORY AND APPROVAL
4.3.4.3. HIGH PRICING PRESSURE AND DECREASE IN CEALING PRICES
4.3.4.4. PATENT EXPIRY AND PATENT CLIFF
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 EXECUTIVE SUMMARY
6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. ORAL DRUG DELIVERY, BY FORM
6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. TABLETS
6.2.2.2. CAPSULES
6.2.2.3. POWDER
6.2.2.4. PILLS
6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. SOLUTIONS
6.2.2.2. SYRUPS
6.2.2. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. GELS
6.2.2.2. EMULSIONS
6.2.2.3. ELIXIRS
6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
6.3.1. METERED DOSE INHALERS (MDI)
6.3.2. DRY POWDER INHALERS (DPI)
6.3.3. NEBULIZERS
6.3.3.1. JET NEBULIZERS
6.3.3.2. ULTRASONIC NEBULIZERS
6.3.3.3. SOFT MIST NEBULIZERS
6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
6.4.1.1.1. GLASS
6.4.1.1.2. PLASTIC
6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
6.4.2.2.1. FILLABLE
6.4.2.2.2. PRE-FILLED
6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
6.4.3.3.1. REUSABLE SYRIGES
6.4.3.3.2. DISPOSABLE SYRINGES
6.4.3.4. SELF INJECTION DEVICES
6.4.3.5. NEEDLE FREE INJECTORS
6.4.3.6. AUTOINJECTORS
6.4.3.7. PEN INJECTORS
6.4.3.8. WEARABLE INJCTORS
6.4.3.9. OTHERS
6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
6.4.2.3. LONG ACTING INJECTION FORMULATIONS
6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.5.1.1. DRUG COATED CONTACT LENSES
6.5.1.2. OCCULAR INSERTS
6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.1.1. EYE DROPS
6.5.2.1.2. SPRAYS
6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.2.1. GELS
6.5.2.2.2. OINTMENTS
6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
6.6.1. NASAL DROPS
6.6.2. NASAL SPRAYS
6.6.3. NASAL POWDERS
6.6.4. NASAL GELS
6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.7.1.1. TRANSDERMAL PATCHES
6.7.1.2. TRANSDERMAL GELS
6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.1.1. SOLUTIONS
6.7.2.1.2. SUSPENSIONS
6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.2.1. GELS
6.7.2.2.2. CREAMS
6.7.2.2.3. OINTMENTS
6.7.2.2.4. PASTES
6.7.2.2.5. LOTIONS
6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.3.1. SUPPOSITORIES
6.7.2.3.2. POWDERS
6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.1.1. BUCCAL DRUG DELIVERY
6.9.1.2. SUBLINGUAL DRUG DELIVERY
6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY
7 DRUG DELIVERY DEVICES MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. COMMUNITY HEALTHCARE
7.6. OTHERS
8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.6. MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.10. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11 DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES
11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
11.2 JOHNSON & JOHNSON
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
11.3 NOVARTIS AG
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
11.4 PFIZER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
11.5 F. HOFFMANN-LA ROCHE AG
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
11.6 GLAXOSMITHKLINE PLC
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
11.7 MERCK & CO.
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
11.8 ANTARES PHARMA, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
11.9 3M
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 SANOFI
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 BECTON, DICKINSON AND COMPANY
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.10 NEMERA
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
11.11 CIMA LABS, INC.
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
11.12 DALI MEDICAL DEVICES
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.5 DATA BRIDGE ANALYSIS
11.13 ALKERMES
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14 FOAMIS
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.5 DATA BRIDGE ANALYSIS
11.15 YPSOMED
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.5 DATA BRIDGE ANALYSIS
11.16 SKYEPHARMA AG
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17 VALEANT PHARMACEUTICALS
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.5 DATA BRIDGE ANALYSIS
11.18 DSM BIOMEDICAL
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.5 DATA BRIDGE ANALYSIS
11.19 CATALENT, INC.
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE GLOBAL DRUG DELIVERY DEVICES MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. GLOBAL DRUG DELIVERY DEVICES MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3 MARKET LANDSCAPE SUMMARY
4 PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. GLOBAL DRUG DELIVERY DEVICES MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
4.3.1.2. TECHNOLOGICAL DEVELOPMENT AND GROWTH IN BIOLOGICS
4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
4.3.2. RESTRAINTS
4.3.2.1. RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
4.3.2.2. HIGH PRICING OF PATENTED DRUGS AND LIMITED AVAILABILITY
4.3.3. OPPURTUNITIES
4.3.3.1. RISING ACCEPTANCE OF SELF ADMINISTERING DRUGS
4.3.3.2. RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS
4.3.3.3. RISING TREND OF ACQUISITION
4.3.3.4. FOCUS ON PATEINT NEEDS
4.3.3.5. DEVELOPING AND NEW EMERGING REVENUE POCKETS
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. EXPENSIVE AND STRINGENT REGULATORY AND APPROVAL
4.3.4.3. HIGH PRICING PRESSURE AND DECREASE IN CEALING PRICES
4.3.4.4. PATENT EXPIRY AND PATENT CLIFF
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5 EXECUTIVE SUMMARY
6 DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. ORAL DRUG DELIVERY, BY FORM
6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. TABLETS
6.2.2.2. CAPSULES
6.2.2.3. POWDER
6.2.2.4. PILLS
6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. SOLUTIONS
6.2.2.2. SYRUPS
6.2.2. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
6.2.2.1. GELS
6.2.2.2. EMULSIONS
6.2.2.3. ELIXIRS
6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
6.3.1. METERED DOSE INHALERS (MDI)
6.3.2. DRY POWDER INHALERS (DPI)
6.3.3. NEBULIZERS
6.3.3.1. JET NEBULIZERS
6.3.3.2. ULTRASONIC NEBULIZERS
6.3.3.3. SOFT MIST NEBULIZERS
6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
6.4.1.1.1. GLASS
6.4.1.1.2. PLASTIC
6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
6.4.2.2.1. FILLABLE
6.4.2.2.2. PRE-FILLED
6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
6.4.3.3.1. REUSABLE SYRIGES
6.4.3.3.2. DISPOSABLE SYRINGES
6.4.3.4. SELF INJECTION DEVICES
6.4.3.5. NEEDLE FREE INJECTORS
6.4.3.6. AUTOINJECTORS
6.4.3.7. PEN INJECTORS
6.4.3.8. WEARABLE INJCTORS
6.4.3.9. OTHERS
6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
6.4.2.3. LONG ACTING INJECTION FORMULATIONS
6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.5.1.1. DRUG COATED CONTACT LENSES
6.5.1.2. OCCULAR INSERTS
6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.1.1. EYE DROPS
6.5.2.1.2. SPRAYS
6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
6.5.2.2.1. GELS
6.5.2.2.2. OINTMENTS
6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
6.6.1. NASAL DROPS
6.6.2. NASAL SPRAYS
6.6.3. NASAL POWDERS
6.6.4. NASAL GELS
6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.7.1.1. TRANSDERMAL PATCHES
6.7.1.2. TRANSDERMAL GELS
6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.1.1. SOLUTIONS
6.7.2.1.2. SUSPENSIONS
6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.2.1. GELS
6.7.2.2.2. CREAMS
6.7.2.2.3. OINTMENTS
6.7.2.2.4. PASTES
6.7.2.2.5. LOTIONS
6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.7.2.3.1. SUPPOSITORIES
6.7.2.3.2. POWDERS
6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.1.1. BUCCAL DRUG DELIVERY
6.9.1.2. SUBLINGUAL DRUG DELIVERY
6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY
7 DRUG DELIVERY DEVICES MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. COMMUNITY HEALTHCARE
7.6. OTHERS
8 DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9 DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.1.2. EUROPE
9.1.2.1. GERMANY
9.1.2.2. FRANCE
9.1.2.3. U.K.
9.1.2.4. ITALY
9.1.2.5. SPAIN
9.1.2.6. RUSSIA
9.1.2.7. TURKEY
9.1.2.8. BELGIUM
9.1.2.9. NETHERLANDS
9.1.2.10. SWITZERLAND
9.1.2.11. REST OF EUROPE
9.1.3. ASIA-PACIFIC (APAC)
9.1.3.1. JAPAN
9.1.3.2. CHINA
9.1.3.3. SOUTH KOREA
9.1.3.4. INDIA
9.1.3.5. AUSTRALIA
9.1.3.6. SINGAPORE
9.1.3.7. THAILAND
9.1.3.8. MALAYSIA
9.1.3.9. INDONESIA
9.1.3.10. PHILIPPINES
9.1.3.11. REST OF APAC
9.1.4. LATIN AMERICA
9.1.4.1. BRAZIL
9.1.4.2. REST OF LATIN AMERICA
9.1.5. MIDDLE EAST AND AFRICA
9.1.5.1. SOUTH AFRICA
9.1.5.2. REST OF MIDDLE EAST AND AFRICA
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10 DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE
10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.6. MIDDLE EAST AND AFRICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.10. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11 DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES
11.1 BAYER AG
11.1.1 COMPANY OVERVIEW
11.1.2 SWOT ANALYSIS
11.1.3 REVENUE ANALYSIS
11.1.4 PRODUCT PORTFOLIO
11.1.5 RECENT DEVELOPEMENTS
11.1.5 DATA BRIDGE ANALYSIS
11.2 JOHNSON & JOHNSON
11.2.1 COMPANY OVERVIEW
11.2.2 SWOT ANALYSIS
11.2.3 REVENUE ANALYSIS
11.2.4 PRODUCT PORTFOLIO
11.2.5 RECENT DEVELOPEMENTS
11.2.5 DATA BRIDGE ANALYSIS
11.3 NOVARTIS AG
11.3.1 COMPANY OVERVIEW
11.3.2 SWOT ANALYSIS
11.3.3 REVENUE ANALYSIS
11.3.4 PRODUCT PORTFOLIO
11.3.5 RECENT DEVELOPEMENTS
11.3.5 DATA BRIDGE ANALYSIS
11.4 PFIZER, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 SWOT ANALYSIS
11.4.3 REVENUE ANALYSIS
11.4.4 PRODUCT PORTFOLIO
11.4.5 RECENT DEVELOPEMENTS
11.4.5 DATA BRIDGE ANALYSIS
11.5 F. HOFFMANN-LA ROCHE AG
11.5.1 COMPANY OVERVIEW
11.5.2 SWOT ANALYSIS
11.5.3 REVENUE ANALYSIS
11.5.4 PRODUCT PORTFOLIO
11.5.5 RECENT DEVELOPEMENTS
11.5.5 DATA BRIDGE ANALYSIS
11.6 GLAXOSMITHKLINE PLC
11.6.1 COMPANY OVERVIEW
11.6.2 SWOT ANALYSIS
11.6.3 REVENUE ANALYSIS
11.6.4 PRODUCT PORTFOLIO
11.6.5 RECENT DEVELOPEMENTS
11.6.5 DATA BRIDGE ANALYSIS
11.7 MERCK & CO.
11.7.1 COMPANY OVERVIEW
11.7.2 SWOT ANALYSIS
11.7.3 REVENUE ANALYSIS
11.7.4 PRODUCT PORTFOLIO
11.7.5 RECENT DEVELOPEMENTS
11.7.5 DATA BRIDGE ANALYSIS
11.8 ANTARES PHARMA, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 SWOT ANALYSIS
11.8.3 REVENUE ANALYSIS
11.8.4 PRODUCT PORTFOLIO
11.8.5 RECENT DEVELOPEMENTS
11.8.5 DATA BRIDGE ANALYSIS
11.9 3M
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 SANOFI
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.9 BECTON, DICKINSON AND COMPANY
11.9.1 COMPANY OVERVIEW
11.9.2 SWOT ANALYSIS
11.9.3 REVENUE ANALYSIS
11.9.4 PRODUCT PORTFOLIO
11.9.5 RECENT DEVELOPEMENTS
11.9.5 DATA BRIDGE ANALYSIS
11.10 NEMERA
11.10.1 COMPANY OVERVIEW
11.10.2 SWOT ANALYSIS
11.10.3 REVENUE ANALYSIS
11.10.4 PRODUCT PORTFOLIO
11.10.5 RECENT DEVELOPEMENTS
11.10.5 DATA BRIDGE ANALYSIS
11.11 CIMA LABS, INC.
11.11.1 COMPANY OVERVIEW
11.11.2 SWOT ANALYSIS
11.11.3 REVENUE ANALYSIS
11.11.4 PRODUCT PORTFOLIO
11.11.5 RECENT DEVELOPEMENTS
11.11.5 DATA BRIDGE ANALYSIS
11.12 DALI MEDICAL DEVICES
11.12.1 COMPANY OVERVIEW
11.12.2 SWOT ANALYSIS
11.12.3 REVENUE ANALYSIS
11.12.4 PRODUCT PORTFOLIO
11.12.5 RECENT DEVELOPEMENTS
11.12.5 DATA BRIDGE ANALYSIS
11.13 ALKERMES
11.13.1 COMPANY OVERVIEW
11.13.2 SWOT ANALYSIS
11.13.3 REVENUE ANALYSIS
11.13.4 PRODUCT PORTFOLIO
11.13.5 RECENT DEVELOPEMENTS
11.13.5 DATA BRIDGE ANALYSIS
11.14 FOAMIS
11.14.1 COMPANY OVERVIEW
11.14.2 SWOT ANALYSIS
11.14.3 REVENUE ANALYSIS
11.14.4 PRODUCT PORTFOLIO
11.14.5 RECENT DEVELOPEMENTS
11.14.5 DATA BRIDGE ANALYSIS
11.15 YPSOMED
11.15.1 COMPANY OVERVIEW
11.15.2 SWOT ANALYSIS
11.15.3 REVENUE ANALYSIS
11.15.4 PRODUCT PORTFOLIO
11.15.5 RECENT DEVELOPEMENTS
11.15.5 DATA BRIDGE ANALYSIS
11.16 SKYEPHARMA AG
11.16.1 COMPANY OVERVIEW
11.16.2 SWOT ANALYSIS
11.16.3 REVENUE ANALYSIS
11.16.4 PRODUCT PORTFOLIO
11.16.5 RECENT DEVELOPEMENTS
11.16.5 DATA BRIDGE ANALYSIS
11.17 VALEANT PHARMACEUTICALS
11.17.1 COMPANY OVERVIEW
11.17.2 SWOT ANALYSIS
11.17.3 REVENUE ANALYSIS
11.17.4 PRODUCT PORTFOLIO
11.17.5 RECENT DEVELOPEMENTS
11.17.5 DATA BRIDGE ANALYSIS
11.18 DSM BIOMEDICAL
11.18.1 COMPANY OVERVIEW
11.18.2 SWOT ANALYSIS
11.18.3 REVENUE ANALYSIS
11.18.4 PRODUCT PORTFOLIO
11.18.5 RECENT DEVELOPEMENTS
11.18.5 DATA BRIDGE ANALYSIS
11.19 CATALENT, INC.
11.19.1 COMPANY OVERVIEW
11.19.2 SWOT ANALYSIS
11.19.3 REVENUE ANALYSIS
11.19.4 PRODUCT PORTFOLIO
11.19.5 RECENT DEVELOPEMENTS
11.19.5 DATA BRIDGE ANALYSIS
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
